Clinical e-news
The newsletter designed to keep the FibroScan® community up-to-date on clinical news and resources.
The following articles are the latest clinical peer-reviewed publications on liver health management.
These new Baveno VIII guidelines further reinforce FibroScan® as the reference non-invasive platform across the entire portal hypertension pathway for the management of patients with advanced chronic liver disease independent of etiology.
In this European multicenter study of patients with cACLD, predominantly due to metabolic diseases, SSM by VCTE® at 100 Hz significantly improved non-invasive diagnosis of CSPH compared to standard methods. The comprehensive model (NICER) incorporating SSM, LSM, platelet count, and BMI establishes a new standard for CSPH risk stratification, enhancing access to disease-modifying treatments for these patients.
The FIB-4 score / VCTE® algorithm showed excellent diagnostic performance, demonstrating its applicability for routine screening in diabetology.
- Effective Screening: A two-step strategy (FIB-4 score followed by VCTE®) effectively identifies patients at high risk of advanced fibrosis.
- Noninvasive Test Performance: FIB-4 outperformed NFS and MAF-5, with a high negative predictive value (97.2%) for ruling out advanced fibrosis.
- Referral to Specialized Care: The FIB-4/VCTE® strategy led to appropriate referrals for hepatology care, though 2% of referrals were false positives.
- Practical for Clinics: The two-step approach is practical and effective for identifying high-risk patients in diabetology and nutrition clinics.
This cross-sectional study from Sweden demonstrated that screening for liver fibrosis using VCTE® during routine retina scans in people with type 2 diabetes is highly accepted and feasible, with over half showing metabolic dysfunction-associated steatotic liver disease and 7.4% confirmed with significant fibrosis.
The objective of this study was to review clinical evidence on clinical utility and to establish consensus guidelines for non-invasive tests, in assessing liver fibrosis in people living with alpha-1 antitrypsin deficiency.
VCTE® represents a particularly valuable approach for post-Fontan patients, given the increased procedural risks associated with invasive liver assessment in this population.
The objective of this study was to evaluate the relationship between LSM by VCTE® and FALD, establish diagnostic cut-off values for FALD and advanced FALD, and assess the correlation between LSM and clinically significant outcomes.
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) affects 1 in 4 people globally, with particularly high rates among those with type 2 diabetes, where 2 in 3 have fatty liver and up to 38% develop advanced fibrosis or cirrhosis. Since 2024, updated European guidelines recommend a two-step screening approach: a simple blood test (FIB-4) followed by Liver Stiffness Measurement (LSM) by FibroScan® device to identify high-risk patients.
This study tested the algorithm on over 1,000 adults with type 2 diabetes who visited a diabetes clinic. Those with a result suggesting increased liver risk received further testing, including imaging and, when needed, liver biopsy. The study evaluates the systematic implementation of the EASL-EASD screening algorithm within a real-world diabetology clinic setting.
With new drug treatments emerging for MASLD, there is an urgent clinical need for simple, widely available, non-invasive tools that can identify patients at risk of disease progression and monitor their response to therapy. This study evaluated whether 1-year changes in FibroScan®-derived data: liver stiffness measurement (LSM) and controlled attenuation parameter (CAP), alongside FIB-4 and serum ALT, can predict liver-related outcomes in patients with MASLD and serve as practical non-invasive tools to guide and monitor pharmacological treatment decisions.